Nature Medicine · 9 July 2026 · From issue 04
A new cell transplant for Parkinson's disease looked safe in a small early trial.
G. Paul, H. Bjartmarz et al., Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial, Nature Medicine.
Doctors tried a new treatment for Parkinson's disease. It uses lab grown brain cells to replace cells the disease destroys. Eight people got the cell transplant into their brains. Seven finished a year of follow up. One person died from a lung infection. No safety problems came from the cells themselves. Most risks came from the drugs used to stop the body rejecting the new cells. Brain scans showed no signs of tumors forming.
Integrity screen: passed (3 checks) Checked 17 August 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature Medicine). Read the source
This screen checks process signals. It does not tell you the findings are true.